ARS Pharma: Cost Cuts + Revenue Focus Create a Practical Swing Buy
ARS Pharma has a new CEO implementing a clear two-pronged program: reduce operating burn and accelerate commercial execution for core products. That combination is rare in small-cap biotech: fewer cash worries and the potential for visible revenue acceleration. This trade idea lays out an entry at $3.25, a stop at $2.50 and a primary target of $6.2…